Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
All content for Breast Cancer Conversations is the property of SurvivingBreastCancer.org and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
268. Revolutionizing Breast Cancer Detection with JP Parthasarathy founder and CEO of Astrin Biosciences
Breast Cancer Conversations
30 minutes
1 month ago
268. Revolutionizing Breast Cancer Detection with JP Parthasarathy founder and CEO of Astrin Biosciences
Love the episode? Send us a text! In this conversation, Laura Carfang interviews JP Parthasarathy, the founder and CEO of Astran Biosciences, about the critical topic of breast cancer, particularly focusing on breast density and its implications for women's health. They discuss the importance of understanding breast density, the advancements in early cancer detection technologies, and the ongoing clinical trials aimed at improving screening methods. JP shares insights into the science behind ...
Breast Cancer Conversations
Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
